Sandra Leung net worth and biography

Sandra Leung Biography and Net Worth

Sandy Leung is the Executive Vice President and General Counsel of Bristol Myers Squibb Company. She leads the worldwide Law Department and is responsible for a wide range of legal areas including intellectual property, commercial and regulatory law, litigation, corporate governance, securities and transactions including licensing, acquisitions and divestitures. She also has responsibility for Compliance & Ethics, Environment, Health & Safety, Corporate Security and Corporate Philanthropy.

Sandy is the Executive Sponsor of Bristol Myers Squibb’s BOLD (Black Organization for Leadership and Development) People & Business Resource Group.

Sandy joined Bristol Myers Squibb in 1992 as a staff attorney in the litigation department. She was promoted to positions of increasing responsibility and was elected Corporate Secretary in 1999. In September 2006, she was appointed Interim General Counsel. In February 2007, she was named General Counsel.

Sandy began her legal career as Assistant District Attorney at the Manhattan District Attorney’s Office in New York City where she was an original member of the Child Abuse Bureau. She ended her prosecutorial career, after trying more than 40 jury trials to verdict, as a member of the prestigious Homicide Investigations Unit where she conducted investigations of unsolved homicides linked with drug gang activity.

Sandy is on the board of directors of the Asian-American Legal Defense and Education Fund and the board of directors of the Minority Corporate Counsel Association.

Sandy is a graduate of Tufts University and Boston College Law School.

What is Sandra Leung's net worth?

The estimated net worth of Sandra Leung is at least $22.15 million as of June 6th, 2022. Ms. Leung owns 308,627 shares of Bristol-Myers Squibb stock worth more than $22,150,160 as of September 29th. This net worth estimate does not reflect any other investments that Ms. Leung may own. Additionally, Ms. Leung receives an annual salary of $2,730,000.00 as EVP at Bristol-Myers Squibb. Learn More about Sandra Leung's net worth.

How old is Sandra Leung?

Ms. Leung is currently 61 years old. There are 8 older executives and no younger executives at Bristol-Myers Squibb. Learn More on Sandra Leung's age.

What is Sandra Leung's salary?

As the EVP of Bristol-Myers Squibb, Ms. Leung earned a total compensation package of $6,161,584.00 in 2021. Ms. Leung earned a salary of $1,100,196.00, stock awards of $3,434,134.00, non-equity compensation of $1,298,162.00, and other compensation of $329,092.00.There are 3 executives that earn more than Ms. Leung. The highest earning executive at Bristol-Myers Squibb is Dr. Giovanni Caforio M.D., Chairman & CEO, who commands a salary of $5,820,000.00 per year. Learn More on Sandra Leung's salary.

How do I contact Sandra Leung?

The corporate mailing address for Ms. Leung and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected] Learn More on Sandra Leung's contact information.

Has Sandra Leung been buying or selling shares of Bristol-Myers Squibb?

Sandra Leung has not been actively trading shares of Bristol-Myers Squibb in the last ninety days. Most recently, Sandra Leung sold 65,000 shares of the business's stock in a transaction on Monday, June 6th. The shares were sold at an average price of $74.89, for a transaction totalling $4,867,850.00. Following the completion of the sale, the executive vice president now directly owns 308,627 shares of the company's stock, valued at $23,113,076.03. Learn More on Sandra Leung's trading history.

Who are Bristol-Myers Squibb's active insiders?

Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Sandra Leung (EVP), Dinesh Paliwal (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.

Are insiders buying or selling shares of Bristol-Myers Squibb?

During the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 530,335 shares worth more than $37,240,689.55. The most recent insider tranaction occured on September, 20th when CEO Giovanni Caforio sold 25,000 shares worth more than $1,742,750.00. Insiders at Bristol-Myers Squibb own 0.1 % of the company. Learn More about insider trades at Bristol-Myers Squibb.

Information on this page was last updated on 9/20/2022.

Sandra Leung Insider Trading History at Bristol-Myers Squibb

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/6/2022Sell65,000$74.89$4,867,850.00308,627View SEC Filing Icon  
8/13/2020Sell141,420$63.24$8,943,400.80432,744View SEC Filing Icon  
12/4/2017Sell156,582$63.37$9,922,601.34584,373View SEC Filing Icon  
3/6/2017Sell92,405$57.02$5,268,933.10488,063View SEC Filing Icon  
5/6/2016Sell72,544$70.39$5,106,372.16444,507View SEC Filing Icon  
2/17/2016Sell10,152$63.57$645,362.64309,547View SEC Filing Icon  
2/17/2015Sell11,746$60.39$709,340.94View SEC Filing Icon  
2/14/2014Sell10,490$54.28$569,397.20195,855View SEC Filing Icon  
See Full Table

Sandra Leung Buying and Selling Activity at Bristol-Myers Squibb

This chart shows Sandra Leung's buying and selling at Bristol-Myers Squibb by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb logo
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Read More

Today's Range

Now: $71.71
Low: $71.16
High: $72.61

50 Day Range

MA: $71.89
Low: $66.75
High: $75.57

2 Week Range

Now: $71.71
Low: $53.22
High: $80.59

Volume

9,454,536 shs

Average Volume

13,061,337 shs

Market Capitalization

$153.12 billion

P/E Ratio

23.82

Dividend Yield

3.00%

Beta

0.43
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January…

And now, he’s issuing a brand-new warning – along with a unique solution.
Details here.